Financial Services
Oaktree Acquisition Corp. III Life Sciences(OACC)
Live Price
Offline$10.66
+0.00% today
1Y Change
+1.53%
Window
Jun 25, 2025 → Jun 22, 2026
- Market Cap
- $260.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +453.5%
- Dividend Yield
- 0.0%
Coverage: 248 bars · Jun 25, 2025 → Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Oaktree Acquisition Corp. III Life Sciences (OACC) is a Financial Services stock with a market cap of $260.00M and listed on NASDAQ. The stock last traded around $10.66 and up 1.5% across the available one-year price window (Jun 25, 2025 → Jun 22, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +453.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +453.5%, free cash flow -235698.3% with operating margin 0.0% and ROIC -0.6%. Valuation already assumes a fairly strong business story at P/E 35.8. Stock Foundry combines OACC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +3.4% peer median
Operating Margin
Below sector median
0.0% vs +4.7% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +453.5%, while operating margin sits near 0.0%.
Benchmark Edge
OACC vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OACC
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OACC Max Drawdown
-1.84%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OACC and SPY.
Company Overview
Oaktree Acquisition Corp. III Life Sciences
NASDAQ Global Market
Oaktree Acquisition Corp. III Life Sciences focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to acquire companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was incorporated in 2024 and is based in Los Angeles, California.
- Leadership
- Zaid Pardesi
- IPO Date
- Dec 16, 2024
- Employees
- 3
- Street Address
- 333 South Grand Avenue
- Mailing
- Los Angeles, CA, 90071
- Region
- Los Angeles, CA, US
- Reporting Currency
- USD
- Investor Line
- 213 830 6300
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 35.8
- EV/EBITDA
- 285.4
- Price/Sales
- —
- Price/Book
- 1.3
Growth
- Revenue
- 0.0%
- EPS
- +453.5%
- Free Cash Flow
- -235698.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 3.8%
- ROIC
- -0.6%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 1.19
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.